IPA Advances AI-Discovered Universal Dengue Vaccine
Manufacturing of validated dengue epitope underway; proprietary immunization research in rabbit mannequin to evaluate monoclonal antibody (mAb) responses.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Firm”), a biotherapeutics firm delivering superior options in biologics and drug discovery in the present day introduced the following milestone in its common dengue vaccine program. Constructing on its June bulletins confirming the invention and validation of a uniquely conserved dengue epitope utilizing its LENSai
platform powered by patented HYFT® expertise, the Firm has up to date that they’re now advancing to pre-clinical manufacturing for in vivo (in animal) testing and virus neutralization evaluation.
The manufactured product can be utilized in proprietary immunization protocols at IPA’s Canadian facility. These research, carried out in a rabbit mannequin, are designed to guage whether or not the vaccine candidate elicits sturdy monoclonal antibody (mAb) responses—an important step towards translational growth.
“That is the pure subsequent step in our journey from AI discovery to real-world validation,” stated Dr. Jennifer Bathtub, CEO of ImmunoPrecise. “We’ve proven that HYFT expertise can determine vaccine targets that others miss — distinctive targets which might be conserved, particular, and immunologically related. Now we’re now transferring into manufacturing and dwell immunization research, the place the query turns into: can this goal elicit a strong and protecting antibody response? That is the place discovery turns into translational actuality, with dengue as the primary instance of what our platform can obtain throughout infectious illnesses.”
The science behind the step:
- AI Discovery → Manufacturing: HYFT-guided evaluation revealed a discontiguous dengue epitope conserved throughout all 4 virus serotypes.
- Validated Security & Immunogenicity: In silico screens confirmed immune activation potential (B- and T-cell responses), structural stability, and complete security towards host proteomes.
- Now Coming into Immunization Research: The product is being synthesized and can be utilized in rabbit fashions to evaluate whether or not it elicits particular monoclonal antibodies — a vital proof level for vaccine growth.
A platform strategy, not only a vaccine:
This development highlights IPA’s end-to-end benefit: combining AI-native discovery with in-house wet-lab validation. With regulators just like the U.S. FDA encouraging predictive, human-relevant approaches that scale back reliance on animal testing, ImmunoPrecise’s in silico-to-in vivo workflow represents a forward-looking mannequin for next-generation vaccine R&D.
By making use of the identical methodology throughout pathogens, IPA is positioning its LENSai/HYFT platform as a flexible discovery engine — not just for dengue, but additionally for different infectious illnesses and immuno-oncology targets.
The put up IPA Advances AI-Discovered Universal Dengue Vaccine first appeared on AI-Tech Park.
